Evidence map›Paper›PMID 31695423›Full record

ArticleOncoTargets and therapy2019

Nitrogen Permease Regulator-Like-2 Exhibited Anti-Tumor Effects And Enhanced The Sensitivity Of Colorectal Cancer Cells To Oxaliplatin And 5-Fluorouracil.

Aiyun Liu, Jiutao Qiao, Liyuan He, Zhangmeng Liu, Jing Chen, Fenghua Pei, Yaju Du

Open access · goldAbstract read
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. eLife · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Improving anti-tumor outcomes for colorectal cancer therapy throughAmerican journal of translational research · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Aiyun LiuDepartment of Gastroenterology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.ORCID 0000-0003-0850-2868
Jiutao QiaoDepartment of Orthopedics, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
Liyuan HeDepartment of Gastroenterology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
Zhangmeng LiuDepartment of Gastroenterology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
Jing ChenDepartment of Gastroenterology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.ORCID 0000-0001-8954-4888
Fenghua PeiDepartment of Gastroenterology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
Yaju DuDepartment of Gastroenterology, The Second Affiliated Hospital of Harbin Medical University, Harbin, People's Republic of China.
Harbin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is one of the most common malignant tumors in the world. Our previous study revealed that nitrogen permease regulator-like-2 (NPRL2), a promising anti-tumor gene, was downregulated at both the blood and tissue levels in CRC patients compared with that in healthy individuals. PURPOSE: This study aims to explore the role of NPRL2 in CRC.

methodsHerein, we constructed NPRL2 overexpression lentivirus vectors and transfected them into HT29 cells. The transfected cells were inoculated subcutaneously into nude mice. Tumor growth, pathology, apoptosis, and the protein expression of caspase-3, caspase-7, Bax, Bcl-2, and phosphorylated protein kinase B (p-Akt) were evaluated. To further explore whether NPRL2 could reduce drug resistance of CRC cells against oxaliplatin (L-OHP) and 5-fluorouracil (5-FU), we constructed a tumor model using HT29 cells. The tumor model was treated with lentiviral particles assembled with vectors encoding NPRL2 and exposed to L-OHP and 5-FU. Tumor growth, pathology, apoptosis, and the protein expression of caspase-3, caspase-7, Bax, Bcl-2, p-Akt, P-glycoprotein (P-gp), and multidrug resistance protein 1 (MRP1) were evaluated.

resultsThe results indicated that in the in vivo CRC xenograft model, NPRL2 reduced the tumor volume and weight and enhanced apoptosis. Our results also confirmed that NPRL2 enhanced the sensitivity of CRC cells to L-OHP and 5-FU. Our studies further demonstrated that NPRL2 exerted anti-tumor and anti-drug resistance effects through the caspase-3, caspase-7, Bax, Bcl-2, Akt, P-gp, and MRP1 pathways.

conclusionOur present work demonstrated that NPRL2 exhibited anti-tumor effects and enhanced the sensitivities of CRC cells to L-OHP and 5-FU through the P-gp and MRP1 pathways.

Indexed as

apoptosiscolorectal cancerdrug resistanceMRP1NPRL2P-gp

Identifiers

PMID31695423
PMCPMC6805118
OpenAlexW2981079794

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.